Today Stories

Fresenius, via its operating company Fresenius Kabi, and Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technology, have entered an agreement to provide the integration of the IRO® platform with Fresenius Kabi’s upstream and downstream processing technologies. The successful integration of these leading technology platforms provides a streamlined, closed workflow for cell therapy manufacturing that can reduce process steps, tube- and bag-based transfers, and operator touch time. This collaboration underscores Ori Biotech and Fresenius Kabi’s shared commitment to driving innovation and developing widespread patient access to life-saving cell and gene therapies. All to help bring cell and gene therapies to market faster and more efficiently, in line with #FutureFresenius.…

CLOSE Nearly 20,000 Big Ten students, alumni and fans across the country donated blood as part of the Abbott-Big Ten nationwide competition this college football season, helping save as many as 60,000 lives Nebraska's win was announced at the Discover Big Ten Football Championship Game where the university received $1 million from global healthcare company Abbott to advance student and community health The competition, which will be back next fall, aims to help combat the greatest need for blood in a generation, while also helping create new lifelong blood donors ABBOTT PARK, Ill., and INDIANAPOLIS, Dec. 7, 2024 /PRNewswire/ -- This college football season, Abbott (NYSE: ABT) and the Big Ten put fandom and the hearts of Big Ten communities to the test with their inaugural blood…

Scientists from The University of Manchester have developed a pioneering process using engineered bacteria to transform complex mixed waste into sustainable biopolymers including human therapeutics such as insulin, and bioplastics. A new study from the Manchester Institute of Biotechnology describes a novel biological method to convert mixed municipal waste-like fractions – including food scraps, plastics, and textiles – into valuable bio-products. This new approach could significantly reduce waste sent to landfills and cut greenhouse gas emissions. Led by Dr Neil Dixon, the team utilised the bacterium Pseudomonas putida, renowned for its resilience and adaptability, to process complex waste streams into bioplastics and even therapeutic proteins. This research offers a promising pathway to…

The investment will benefit millions of patients worldwide, boosting the production of the company's medicines, including those for diabetes and obesity  INDIANAPOLIS, Dec. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion of the Kenosha County, Wisconsin, manufacturing facility that the company acquired earlier this year. This investment will extend the company's global parenteral (injectable) product manufacturing network, helping to meet the growing demand for its diabetes, obesity and future pipeline medicines across therapeutic areas. Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location. The company plans to start construction on the expansion next year. This represents another step in Lilly's hi…

The Hive is aimed at advancing research in life sciences by a novel approach to collaboration - creating an open innovation hub designed to build  close relationships between biotech companies, start-ups, academics, and Almirall scientists The network will be enlarged with the arrival of Admit Therapeutics and Microomics, in addition to the current members of the hub ZeClinics and Centrient Pharmaceuticals   This novel approach to pushing the boundaries of science and innovation in the year of Almirall’s 80th anniversary is part of the company’ s innovation strategy, long-term vision, commitment to patients, and the advancement of healthcare BARCELONA, Spain. December 4th, 2024 – Almirall, a global pharmaceutical company dedicated to medical dermatology, today announced the launch of “Th…

Agreement provides significant, non-dilutive capital to Novavax, further enabling the Company to advance its corporate growth strategy of driving value from its pipeline assets and proven technology platform Provides Novavax with $190 million cash payment in 2024 and additional $10 million in 2025, and annual operating cost reductions of approximately $80 million GAITHERSBURG, Md., Dec. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has signed a definitive agreement to sell its manufacturing facility in Bohumil, Czech Republic to Novo Nordisk for $200 million. The agreement includes a transfer of assets, including a 150,000-square foot state-of-the-art recombinant protein manufac…

A new total-body PET scanner that is quicker for the patient and produces higher quality images for faster and earlier diagnosis and  treatment of illnesses like cancer and heart conditions, was unveiled by Ministers in London yesterday (Wednesday 27 November). The new scanner, one of three becoming operational in the UK, is up to 40 times more sensitive and up to 10 times faster than existing machines, meaning quicker diagnoses and a more detailed reading of the patient's whole body. It will also give researchers unparalleled insights into human biology that ultimately leads to better healthcare. The first of several patients to use the new total body PET scanner at St Thomas’ Hospital in the past month was Sarah Corfield, who has stage 4 melanoma and has been receiving regular PET scans…

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has been lifted to 8th place in the 2024 Access to Medicine Index (ATMI), up from 13th in 2022. This improvement reflects the company’s strategic shift of prioritizing Health Equity as its primary contribution to the United Nations Sustainable Development Goals (UN SDGs).  Every two years the ATMI evaluates the efforts of the world's leading pharmaceutical companies and ranks the top 20 based on their efforts to improve access to medicine in low- and middle-income countries. Today, it has recognized Boehringer Ingelheim's substantial progress across key areas, particularly in Research & Development (R&D) and Product Delivery – due to a strong performance in capacity building and measuring outcomes.  "…

Chris Boshoff to lead all Research and Development functions including Oncology Oncology Unit end-to-end structure to remain intact, reporting to Boshoff Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year. In his new role, Dr. Boshoff will remain a…

Abbott published 'Advancing Diversity in Clinical Trials' to share strategies to support diversified clinical trials in healthcare The company continues to build new partnerships designed to improve diverse enrollment in clinical trials, drive education about the research process, and empower diverse patients to improve their care Now in its third year, Abbott's Diversity in Clinical Trials initiative continues to ensure broad, diverse groups of patients are represented in the clinical trials process ABBOTT PARK, Ill. – Nov. 19, 2024 – Abbott today announced that, in the third year of its multi-million-dollar Diversity in Clinical Trials initiative, the company has published 'Advancing Diversity in Clinical Trials' to share strategies to make clinical research and the teams leading these…

An Taoiseach, Simon Harris, TD, and Abbott Chairman and Chief Executive Officer, Robert Ford, attend official opening More than 800 to be employed at the diabetes technology manufacturing site, which is part of a €440 million investment Abbott is making across two sites in Ireland Facility will have the highest production of FreeStyle Libre® sensors in the world Abbott announces $100,000 grant to The Ireland Funds to support the education of young people from three DEIS schools located in Kilkenny ABBOTT PARK, Illinois – Nov. 18, 2024 – Abbott today marked the official opening of its state-of-the-art manufacturing facility in Kilkenny, Ireland with a ceremony attended by An Taoiseach, Simon Harris, TD, and Abbott Chairman and Chief Executive Officer, Robert Ford. The site is a glob…

PORTAGE, Mich., USA – November 14, 2024 – Stryker (NYSE:SYK), a global leader in medical technologies, announced its launch of the next generation of SurgiCount+ within its sponge management portfolio. Now integrated with Stryker’s Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals. Maternal mortality has been rising in the U.S. for decades,1 with approximately 50,000 cases of severe maternal morbidity occurring each year.2 Notably, 70% of pregnancy-related deaths due to hemorrhage are preventable.3 Stryker’s Triton software includes AI technology that can differentiate blood from…

Newly built 45,000 sq ft facility houses engineering and skilled manufacturing employees at Longbridge Business Park, a specialized hub for science and technology. Waters triples manufacturing footprint while increasing precision machining and metrology capacity to support future growth. New facility was constructed to BREEAM Very Good standard and achieved the highest Energy Performance Certificate rating. LONGBRIDGE, United Kingdom – November 13, 2024 – Waters Corporation (NYSE:WAT) announced the official opening of its new 45,000 square foot manufacturing facility at the Longbridge Business Park in the West Midlands. The new facility more than triples existing operations and enhances the company’s machining capacity to produce critical components for products developed and manufacture…

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumors With the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinations BioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 2025 BioNTech to pay $800 million to acquire 100 percent of the issued share capital and up to $150…

More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1 DRD is a growing epidemic that is expected to increase as the incidence of diabetes escalates across the globe.2,3 There is an urgent need for earlier detection of DRD and novel treatments that work in earlier disease states before vision loss occurs.  Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term collaboration as Boehringer becomes the first pharmaceutical company to join the MTM Vision Consortium. Housed at the University of Michigan, the MTM Vision Consortium aims to unite innovators in the pre-competitive space from universities, f…

AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy. AstraZeneca’s expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts A next generation manufacturing facility for biologics in Maryland Cell therapy manufacturing capacity on the West and East Coasts Specialty manufacturing in Texas Pascal Soriot, Chief Executive Officer, AstraZeneca said: “Our multibillion dollar investment reflects the attractiveness of the business environment together with the…

Professor Meritxell Huch, a director at the Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany receives this year’s Otto Bayer Award for her pioneering research on human organoids / Four early career scientists are honored with the Early Excellence in Science Awards for their boundary breaking research in the fields of Biology, Chemistry, Data Science and Medical Science. Leverkusen, November 6, 2024 – Professor Meritxell Huch receives this year’s Otto Bayer Award. The Otto Bayer Award is presented alternating with the Hansen Family Award every second year. The award recognizes leading scientists working in German-speaking countries for ground-breaking research in chemistry or biochemistry. The award with a prize money of EUR 75,000 was generou…

STRASBOURG, France and BERLIN, Germany, November 05, 2024 / Biotech Newswire / -- Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a leading CDMO in biologics, vaccines and viral vectors, announce that the companies have entered into a license agreement for ProBioGen’s AGE1.CR.pIX® suspension cell line. This partnership aims to add value by combining ProBioGen’s specific production technology with the manufacturing capabilities of Transgene’s individualized cancer vaccine program and its myvac® platform. ProBioGen’s AGE1.CR.pIX suspension cell line showcases innovation and reliability in bioprocessing with a proven track record and is currently in use for multiple late-stage clinical trials.…

Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard have agreed to collaborate on a project to tackle the urgent and unmet needs of people living with mental health conditions. The collaboration will focus on developing first-in-class treatments that address sleep disturbances associated with cognitive impairment in mental health conditions such as schizophrenia or mood disorders, which have a substantial impact on those affected, but also on their care partners and families. One in eight people are currently living with a serious mental health condition worldwide, and one in two people will experience such a condition in their lifetime. Cognitive impairment is one of the core characteristics of mental health co…

Lund, Sweden – SmiLe company Aligned Bio has successfully completed a financing round, securing SEK 19.4 million to accelerate the development and scale up its nanowire production technology. The company has been accepted into the SmiLe incubator program.  The nanotechnology company Aligned Bio has completed a new share issue to take its unique platform for manufacturing semiconductor nanowires toward commercialization. Both existing shareholders and new investors, including SmiLe Inject Capital, participated in the financing round.  What makes Aligned Bio’s technology unique is its ability to detect individual molecules, significantly improving sensitivity in the analysis of biomolecules. The production of nanowires also becomes simpler and thus more cost-effective than with existing tech…